for the main comparison.
| Coenzyme Q10 compared with placebo for primary hypertension | ||||
| Patient population: patients with primary hypertension Settings: primary care in Japan and New Zealand Intervention: coenzyme Q10 100 to 200 mg daily Comparison: placebo | ||||
| Outcomes |
Mean difference in BP mmHg [95% CI] |
No of Participants (studies) | Quality of the evidence (GRADE) | Comments |
|
End of treatment SBP (over 12 weeks) |
‐3.7 mm Hg (‐8.9 to 1.5) |
50 (2) |
⊕⊕⊕⊝ moderate1 | |
|
End of treatment DBP (over 12 weeks) |
‐2.0 mm Hg (‐4.8 to 0.8) |
50 (2) |
⊕⊕⊕⊝ moderate1 | |
| Withdrawals due to adverse effects | 30 (1) |
Effect estimate not available; only one study reported this outcome but had no events in either study arm. | ||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||
1. Downgraded due to large confidence intervals from a small sample size and small number of included studies.